BF
BFRG.US Bullfrog AI Holdings, Inc. Common Stock
- Market cap
- USD 10.0M
- P/E
- -
- P/B
- 1.47x
- ROE
- -130.7%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is BFRG.US undervalued?
Graham numberThe Graham number of Bullfrog AI Holdings, Inc. Common Stock cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Bullfrog AI Holdings, Inc. Common Stock fundamental analysis
No fundamental analysis for Bullfrog AI Holdings, Inc. Common Stock yet.
Bullfrog AI Holdings, Inc. Common Stock stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Bullfrog AI Holdings, Inc. Common Stock
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phas…
Full company profileBullfrog AI Holdings, Inc. Common Stock financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Bullfrog AI Holdings, Inc. Common Stock annual financial statements
| Item | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|
| Income Statement | |||||||
| Revenue | 0.00 | 0.00 | 10.0K | 65.0K | 0.00 | 117K | 372K |
| Gross Profit | 0.00 | 0.00 | 9.20K | 59.8K | -1.72K | 21.9K | 155K |
| Operating Income | -347K | -555K | -2.46M | -5.37M | -7.24M | -6.59M | -6.78M |
| EBITDA | -347K | -555K | -2.45M | -5.28M | -6.97M | -6.49M | -6.68M |
| Net Income | -342K | -586K | -2.80M | -5.36M | -6.99M | -6.50M | -6.64M |
| EPS | -0.06 | -0.10 | -0.46 | -0.89 | -0.85 | -0.63 | -0.35 |
| Balance Sheet | |||||||
| Total Assets | 5.02K | 10.0K | 80.4K | 2.78M | 5.55M | 2.81M | 5.79M |
| Total Liabilities | 546K | 1.02M | 3.14M | 184K | 588K | 672K | 719K |
| Shareholders' Equity | -541K | -1.01M | -3.06M | 2.59M | 4.96M | 2.14M | 5.08M |
| Cash & Short-term Investments | 5.02K | 10.0K | 57.7K | 2.62M | 5.44M | 2.18M | 4.99M |
| Total Debt | 210K | 586K | 1.58M | - | - | - | - |
| Cash Flow | |||||||
| Operating Cash Flow | -212K | -382K | -911K | -6.00M | -5.61M | -5.52M | -6.79M |
| Capital Expenditure | 0.00 | 5.00 | 8.74K | 1.00 | 0.00 | 5.00 | 0.00 |
| Free Cash Flow | -212K | -382K | -920K | -6.00M | -5.61M | -5.52M | -6.79M |
| Ratios | |||||||
| ROE | - | - | - | -206.6% | -140.9% | -304.2% | -130.7% |
| ROA | -6,807.9% | -5,850.2% | -3,487.0% | -192.9% | -126.0% | -231.4% | -114.5% |
| Net Profit Margin | - | - | -28,024.9% | -8,239.8% | - | -5,569.6% | -1,784.0% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Bullfrog AI Holdings, Inc. Common Stock dividends
Bullfrog AI Holdings, Inc. Common Stock has not paid dividends in the last 6 fiscal years.
Who owns Bullfrog AI Holdings, Inc. Common Stock
- Insiders 13.54%
- Institutions 6.38%
- Public & others 80.07%
- Shares outstanding 18.5M
- Free float 16.0M
Top funds holding BFRG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Extended Market Index | 85.8K | 0.46% | -0.17% | Sep 2026 |
| Fidelity Series Total Market Index | 7.18K | 0.04% | 0.00% | Sep 2026 |
| Fidelity Total Market Index | 6.91K | 0.04% | 0.00% | Sep 2026 |
Top institutions holding BFRG.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Citadel Advisors Llc | 362K | 1.95% | 0.00% | Jun 2026 |
| J. Safra Sarasin Holding AG | 114K | 0.61% | 0.00% | Jun 2026 |
| Vanguard Fiduciary Trust Co | 106K | 0.57% | +316.42% | Jun 2026 |
| Geode Capital Management, LLC | 105K | 0.57% | +31.39% | Jun 2026 |
| Vanguard Capital Management, LLC | 91.6K | 0.49% | +37.59% | Jun 2026 |
| Vontobel Holding Ltd. | 70.0K | 0.38% | +84.21% | Jun 2026 |
| Jane Street Group LLC | 66.0K | 0.36% | 0.00% | Jun 2026 |
| FORTEM FINANCIAL GROUP, LLC | 50.0K | 0.27% | 0.00% | Jun 2026 |
| ACT Advisors, LLC | 36.8K | 0.20% | -34.69% | Sep 2026 |
| Northern Trust Corp | 23.5K | 0.13% | 0.00% | Jun 2026 |
| TWO SIGMA SECURITIES, LLC | 21.7K | 0.12% | 0.00% | Jun 2026 |
| StoneX Group Inc | 18.6K | 0.10% | +12.82% | Jun 2026 |
| Susquehanna International Group, LLP | 17.1K | 0.09% | 0.00% | Jun 2026 |
| EWA, LLC | 11.9K | 0.06% | 0.00% | Jun 2026 |
| Virtu Financial LLC | 11.2K | 0.06% | 0.00% | Jun 2026 |
| Tower Research Capital LLC | 6.20K | 0.03% | +13.98% | Jun 2026 |
| Hickory Point Bank & Trust | 2.00K | 0.01% | 0.00% | Jun 2026 |
| Barclays PLC | 1.03K | 0.01% | 0.00% | Jun 2026 |
| EverSource Wealth Advisors, LLC | 486.00 | 0.00% | 0.00% | Jun 2026 |
| UBS Group AG | 7.00 | 0.00% | -99.96% | Jun 2026 |
Bullfrog AI Holdings, Inc. Common Stock company profile
- Company name
- Bullfrog AI Holdings, Inc. Common Stock
- Ticker
- BFRG.US
- Exchange
- USA Stocks
- Listed since
- Feb 13, 2023
- Sector
- Healthcare
- Industry
- Health Care Equipment & Supplies
- Employees
- 9
- Fiscal year end
- December
- Address
- 325 Ellington Boulevard, Gaithersburg, MD, United States, 20878
- Phone
- 240 658 6710
- Website
- bullfrogai.com
About Bullfrog AI Holdings, Inc. Common Stock
Bullfrog AI Holdings, Inc. operates as a digital biopharmaceutical company that focuses on artificial intelligence and machine learning (AI/ML) driven analysis of data sets in medicine and healthcare in the United States. The company offers bfLEAP, an analytical AI/ML platform to analyze preclinical and clinical data for biotechnology and pharmaceutical companies, and other organizations. It also develops BF-222, a novel formulation of mebendazole, which is in the first phase for the treatment of Glioblastoma; BF-223, a novel prodrug of mebendazole, which is in the preclinical stage for the treatment of Glioblastoma; and BF-114, which is in the discovery phase, to treat obesity and chronic liver diseases. The company has licensing agreements with George Washington University for rights to use siRNA targeting Beta2-spectrin in the treatment of human diseases, including hepatocellular carcinoma, obesity, non-alcoholic fatty liver disease, and non-alcoholic steatohepatitis; and Johns Hopkins University for use of a formulation of Mebendazole for the treatment of glioblastoma, and human cancer or neoplastic disease. It has a partnership with the Lieber Institute for Brain Development (LIBD) to enable the discovery and development of precision treatments for CNS disorders. The company was founded in 2017 and is headquartered in Gaithersburg, Maryland.
Bullfrog AI Holdings, Inc. Common Stock management
6- Mr. Vininder SinghFounder, Chairman & CEO · born 1968
- Mr. Joshua Blacher C.P.A., M.B.A.Chief Financial Officer · born 1973
- Mr. J. T. KoffenbergerHead of Information Technology
- Dr. Cetin Savkli Ph.D.Chief AI Advisor & Member of Advisory Board
- Mr. Eric RoosSVP of Business Development & Corporate Strategy
- Mr. John StewartSVP of Commercial Sales